ASH 2022 | Pre-clinical activity of ziftomenib in pediatric KMT2A-rearranged ALL
Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, shares some insights into a pre-clinical study investigating the activity of the menin inhibitor ziftomenib for the treatment of patients with KMT2A-rearranged acute lymphoblastic leukemia (ALL). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Aleta Biotherapeutics: Consultancy; Beam Therapeutics: Research Funding; bluebird bio: Consultancy; Syndax Pharmaceuticals: Consultancy; Kura Oncology: Consultancy, Research Funding; GSK: Consultancy; Incyte Corporation: Research Funding.
